RASSF5

Ras association domain-containing protein 5 · Q8WWW0 · RASSF5 on Sugi Atlas →

0 patent compounds predicted against RASSF5, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RASSF5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer PHASE2COMPLETED
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 PHASE2COMPLETED
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 PHASE2COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases PHASE2UNKNOWN
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas PHASE2COMPLETED
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas PHASE1COMPLETED
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML PHASE1COMPLETED
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
Expression and Function of the Renin-Angiotensin System in the Esophagus EARLY_PHASE1COMPLETED
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus nanACTIVE_NOT_RECRUITING
Long Term Prediction of MASH-related HCC Risk by Proteomics nanNOT_YET_RECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Analysis of Intestinal Microflora Combined With DNA Methylation in Stool to Detect Colorectal Cancer nanUNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
Renal Artery Dopplers in Twin Twin Transfusion Syndrome nanCOMPLETED
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Germline Mutations in Pancreatic Adenocarcinoma nanCOMPLETED
Detection of Genetic Markers of Lung Cancer nanRECRUITING
Markers for Predicting Risk of Breast Cancer in Women of Different Races nanWITHDRAWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
DNA Variations in the Gene in Young Patients With Wilms' Tumor nanCOMPLETED
Identification of New Colorectal Cancer Genes nanCOMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics nanCOMPLETED
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RASSF5 binder may also engage these)

ProteinNameSimilarity
O35141 0.998 O35141 →
Q5EBH1 0.997 Q5EBH1 →
Q9H2L5 0.978 Q9H2L5 →
Q99MK9 0.977 Q99MK9 →
Q8CB96 0.975 Q8CB96 →
Q66T02 0.974 Q66T02 →
P51509 0.974 P51509 →
Q96KN4 0.970 Q96KN4 →
P49797 0.970 P49797 →
Q69Z89 0.970 Q69Z89 →
Q0QWG9 0.970 Q0QWG9 →
Q496Y0 0.970 Q496Y0 →
A4D2P6 0.969 A4D2P6 →
Q4R4I0 0.969 Q4R4I0 →
P70268 0.969 P70268 →
TERF2IP Telomeric repeat-binding factor 2-interacting protein 1 0.968 landscape →
A1A4I4 0.968 A1A4I4 →
Q566C5 0.967 Q566C5 →
Q6NS60 0.967 Q6NS60 →
Q8C190 0.967 Q8C190 →
Q5MNU5 0.967 Q5MNU5 →
Q9NS23 0.967 Q9NS23 →
Q8TBN0 0.967 Q8TBN0 →
Q9BYB0 0.967 Q9BYB0 →
P49796 0.966 P49796 →
Q9WTR8 0.966 Q9WTR8 →
P97260 0.966 P97260 →
Q8HXH0 0.966 Q8HXH0 →
Q7Z5H3 0.966 Q7Z5H3 →
O43566 0.966 O43566 →